Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IGC to .70 next week, Happy St. Patty's day!
I play according to charts,trends and formations as you can see from my charts.
I can see that possibility. I'll definitely be keeping this on my watch list. As always great charts and insight.
Been alerting this since the 1 st leg..she might retrace
This chart looks really strong.
NTS Huge bid support came in, UBSS on bid with huge support at .55
HAUP JAN 23 ALERT 7%
DSTI~NEWS...good luck, michael
http://ih.advfn.com/p.php?pid=nmona&article=51661300
*** DHT... MAjor break out looming if we can cross 128
APPY .78 getting some volume hits at the ask on news just out!
APPY (.77) Results of 503-Patient Clinical Study of AspenBio Pharma's AppyScore(TM) Blood Test Show 97% Negative Predictive Value for Absence of Acute Appendicitis in Children and Adolescents Presenting with Abdominal Pain
Last update: 3/16/2012 2:15:00 PM"Evaluating children and adolescents for appendicitis is difficult... Development of a quick and reliable blood test will provide clinicians with a tool that can be used to help reduce unnecessary exposure to ionizing radiation."David Spiro, M.D., Pediatric Emergency MedicineOregon Health & Science University, AppyScore Clinical Investigator CASTLE ROCK, Colo., Mar 16, 2012 (BUSINESS WIRE) -- --Clinical Data to be presented from the podium at West Region meeting of the Society for Academic Emergency Medicine (SAEM) The results from AspenBio Pharma's (APPY) 503-patient pilot study of AppyScore(TM) will be presented from the podium the upcoming West Region meeting of the Society for Academic Emergency Medicine (SAEM) being held in Las Vegas, March 16-17. AppyScore is a multi-marker blood-based test panel consisting of the company's patented MRP 8/14 biomarker and C-reactive protein, along with white blood cell count. AppyScore is designed to aid emergency physicians in the identification of children and adolescents at low risk when acute appendicitis is suspected due to abdominal pain. The AppyScore test is in development and not yet approved for use. Abdominal pain is the number-one reason for hospital emergency department visits, and appendectomy is the number-one reason for emergency abdominal surgery. The pilot study included pediatric and adolescent patients ages 2-20 with symptoms suspicious for acute appendicitis who were enrolled at 11 hospital sites across the country. Results for the AppyScore test showed a negative predictive value of 97% and sensitivity of 96%. "Evaluating children and adolescents for appendicitis is difficult, and strategies have been sought to improve the precision of the diagnosis," said David Spiro, M.D., a clinical investigator in the AppyScore pilot study and a pediatric emergency medicine specialist at Oregon Health & Sciences University, Portland, Ore. "Development of a quick and reliable blood test will provide clinicians with a tool that can be used to help reduce unnecessary exposure to ionizing radiation." In the U.S., approximately 10 million people annually enter hospital emergency rooms with abdominal pain. Currently, CT scanning is frequently used for screening of appendicitis due to the lack of other more definitive tools. However, CT scans take time, are expensive, and published studies have reported increased concern among clinicians about the potential harmful effects of CT radiation. A single abdominal CT scan exposes patients to a radiation dose equivalent to 100 to 800 chest x-rays, according to a February 2010 report released by the FDA, "Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging." The use of AppyScore has the potential to reduce the number of costly abdominal CT scans and associated exposure to harmful radiation. In addition, radiology procedures can result in significant wait times and patient backlog in hospital emergency rooms. These factors have created an unmet clinical need for a quick blood test that can provide doctors with a high level of confidence that low-risk patients may be conservatively managed and potentially not require CT scans in the workup for possible appendicitis. "An AppyScore pivotal clinical trial is planned for later this year, which will be followed by the submission of results to the FDA for market clearance," added Stephen T. Lundy, president and CEO of AspenBio Pharma. "We also are advancing plans to certify AppyScore with the CE mark, allowing for the potential sale and distribution of AppyScore in regions of Europe before the end of the year." About AspenBio Pharma and AppyScore AspenBio Pharma, Inc. is an emerging in vitro diagnostic company focused on obtaining FDA clearance for its lead product, AppyScore, which is a unique blood-based test in development designed to help physicians manage the large number of patients who enter emergency rooms every year complaining of abdominal pain, many suspected of having acute appendicitis. As a screening test to aid in evaluating patients suspected of appendicitis based on its projected sensitivity and negative predictive value, the AppyScore test is designed to aid in identifying those patients who are at low risk for appendicitis, allowing clinicians to take a more conservative approach to patient management. The current focus of AspenBio's effort is the use of AppyScore in children and adolescents suspicious for the disease as this population is at the highest risk of the long-term health effects associated with CT imaging. AppyScore could potentially decrease radiation exposure risk arising from the use of CT scans performed in triaging pediatric and adolescent patients with abdominal pain, as well as potentially reduce healthcare costs. The company has a large and unique repository of blood samples that provide valuable data regarding the appendicitis condition and additional protein marker information associated with causes of abdominal pain, providing an important resource for product development. For more information, visit . Forward-Looking Statements This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance, cost effectively manufacture and generate revenues from AppyScore and other new products, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended September 30, 2011. SOURCE: AspenBio Pharma, Inc.
Company Contact: AspenBio Pharma, Inc. Gregory Pusey, 303-794-2000 Ext. 207 or Media Contact: Ronald Trahan Associates, Inc. Ronald Trahan, APR, 508-359-4005, Ext. 108 or Investor Relations: Liolios Group, Inc. Ron Both, 949-574-3860Copyright Business Wire 2012
Drys also having a good streak here...
Here is the NTS DD I put together. You can make up your mind from there.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72834871&txt2find=nts|dd
IGC about to turn green...$0.80 next week
DHT the top Bollie we need to close 1.25 or better.. then we are good for Cup and Handle break next week
PEIX no one really knows when Madera Plant will be opening!!
....great...so MADERA PLANT is OPENING IN APRIL....NOT END OF MARCH?
many thanks
(today i loaded IGC big time Augusta!!!!)
IGC, there are all the 100, 200, 300 orders they put through on the BID to get people to sell and then they suck up the big sell orders! With only 13 million in the float, I don't think many shares are left on the street. $.70 for next week is a no brainer!
EDIT, you may be seeing the beginning of the run because the MM's are upping their .51 ASK. They keep upping the price. Weak now into .55!
PEIX just did a $5MILLION or so- stock offering and most times you see PPS drop. PEIX has bounced from low $1 to 1.20 -- makes you wonder why? Also, will the company be using that stock offering to prepare the MADERA PLANT opening in April 2012!!
Its really up to you. I my self think this is a coiled spring here. I think their Q is going to be great. Also all of the DD I have done tells me this is worth more then its trading at. I myself have a good chunk of shares and know many others that do as well. Plus from what I looked at last night It sure looks like their louisiana fiber build out was supposed to really take off last month. I think this next conference call should have lots of good stuff on it. Shares down here are drying up. I mean look at yesterday it dropped .08 on like 1400 shares traded into the close. This things is moving 10% some days on 1K shares or less.
PEIX if they open Madera it means ETHANOL demand increasing and for BIOF it means 40Million Gallons more per year to add to the accounting books. JMHO>>>>>>
Augusta
do you expect a run of PEIX when they announce the Madera Plant opening?
please advise,
Thanks for the update AF!..holding quite a few DHT...good luck, michael
Matt 24d:
How r you?
NTS volume is so low...its hard to buy an important quantity of shares.
what should i do ?
many thanks Matt
STRL (9.36) Subsidiary Road and Highway Builders of California is Apparent Low Bidder on an Approximately $34.4 Million Project in California
Last update: 3/16/2012 11:51:00 AMHOUSTON, Mar 16, 2012 (BUSINESS WIRE) -- Sterling Construction Company, Inc. (nasdaqgs:STRL) ("Sterling" or "the Company") today announced that its subsidiary, Road & Highway Builders of California, was apparent low bidder on a California State Highway 89 project (Contract Number 03-2A9204), for the State of California Department of Transportation valued at approximately $34.4 million. The project consists of rebuilding Highway 89 from the Truckee River Bridge in Tahoe City to Homewood. Work, which includes constructing utility systems, earthwork, HMAC paving, concrete structures and a polyester bridge deck overlay, is expected to begin this summer and be completed in 2015. Patrick T. Manning, Sterling's Chairman and CEO commented, "We're pleased with our continuing expansion into the California market and see numerous opportunities in this geography for Sterling Construction." Sterling is a leading heavy civil construction company that specializes in the building and reconstruction of transportation and water infrastructure in Texas, Utah, Nevada, Arizona, California and other states where there are construction opportunities. Its transportation infrastructure projects include highways, roads, bridges and light rail and its water infrastructure projects include water, wastewater and storm drainage systems.
This press release includes certain statements that fall within the definition of "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Any such statements are subject to risks and uncertainties, including overall economic and market conditions, federal, state and local government funding, competitors' and customers' actions, and weather conditions, which could cause actual results to differ materially from those anticipated, including those risks identified in the Company's filings with the Securities and Exchange Commission. Accordingly, such statements should be considered in light of these risks. Any prediction by the Company is only a statement of management's belief at the time the prediction is made. There can be no assurance that any prediction once made will continue thereafter to reflect management's belief, and the Company does not undertake to update publicly its predictions or to make voluntary additional disclosures of nonpublic information, whether as a result of new information, future events or otherwise. SOURCE: Sterling Construction Company, Inc.
Sterling Construction Company, Inc. Brian Manning, PE EVP & Chief Business Development Officer Elizabeth Brumley EVP & Chief Financial Officer 281-821-9091 or Investor Relations Counsel The Equity Group Inc. Linda Latman, 212-836-9609 Lena Cati, 212-836-9611Copyright Business Wire 2012
PEIX will Madera Plant open by end of March 2012??
$EGT chart is a beauty. Volume is good for a lot of people to participate in the rally.
Let's see who reaches 0.70-0.80 first. $EGT or IGC? Who will get first.
I don't know anything about IGC. But surely $EGT will get there based on all my research over a long period of time.
I have pumping this stock right from 0.22 in early December-Janaury 2011/2012 period.
300,000 shares trade so far.
AF, Thanks for your acknowledgement. Good luck to all your investments.
Do you have any other groups or is it just ihub message board?
IGC next week runner imo
earnings on monday from what i understand. they wont be all that great, but its the drug approval on the line that should keep things in check. im looking forward to seeing what they have to say in regards to that.
PEIX BIOF look reayd for next week!
Thank you NO OTCBB or Pinks -- Thanks good eye!
DHT needs a close of 1.28
Someone remove this post, this is a stinky OTC BB stock, not allowed on this board.
EGT catching up to IGC -- run IGC run
Followers
|
2542
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
659375
|
Created
|
06/03/08
|
Type
|
Free
|
Moderator AugustaFriends | |||
Assistants jobynimble JDUB Mark |
Sign up for Email Updates: http://investorshub.advfn.com/boards/chairmail_sub.asp?board_id=12753
Chart Lessons by IAMGEND - A must learn for all traders
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76625096
Chart tools:
(1) I use http://www.stockcharts.com for charting
(2) For more info on chart formations, see http://www.chartpatterns.com
(3) Chart indicator definitions http://stockcharts.com/education/IndicatorAnalysis/
(4) Explore Level II here-http://www.hotstockmarket.com/forums/showthread.php?t=14938
(5) For a COMPLETE list of indicator meanings http://www.investopedia.com/categories/technicalanalysis.asp
(6) Top insider trades website: http://www.secform4.com/top-lists.htm
BOARD FOR IHUBS HOTTEST CHART PLAYS
http://investorshub.advfn.com/boards/board.aspx?board_id=18372
WHO'S HOT: http://investorshub.advfn.com/boards/hot_people.asp
CHART YOUR STOCKS HERE: http://stockcharts.com/index.html http://www.profitspi.com/
INSTANT TECHNICAL ANALYSIS: http://www.barchart.com/
NEWS FILTER: http://www.marketwatch.com/
GOOD READ: http://www.bloggingstocks.com/
ALL ABOUT TRADERS: http://www.tradersmagazine.com/
TRACK WHAT THE FUNDS ARE DOING - MY FAVORITE SITE!: http://www.mffais.com
COMMENTARY ON EVERYTHING STOCKS: http://www.istockanalyst.com/
BEST ONLINE BROKERAGE:http://www.nobletrading.com/index.php (ask for Efrain)
MARKET MAKERS: http://www.otcbb.com/dynamic/tradingdata/download/mmids.txt
SHORT DATA: http://shortsqueeze.com/
SEC FILINGS: http://www.sec.gov/edgar/searchedgar/companysearch.html
WALL STREET TABLOID: http://dealbreaker.com/
Posts Today
|
5
|
Posts (Total)
|
659375
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |